PATENTED MEDICINE PRICES REVIEW BOARD
Statement of Management Responsibility Including Internal Control Over Financial Reporting

Responsibility for the integrity and objectivity of the accompanying financial statements for the year ended March 31, 2012, and all information contained in these statements rests with the management of Patented Medicine Prices Review Board (the Board). These financial statements have been prepared by management using the Government's accounting policies, which are based on Canadian public sector accounting standards.

Management is responsible for the integrity and objectivity of the information in these financial statements. Some of the information in the financial statements is based on management's best estimates and judgment, and gives due consideration to materiality. To fulfill its accounting and reporting responsibilities, management maintains a set of accounts that provides a centralized record of the Board's financial transactions. Financial information submitted in the preparation of the Public Accounts of Canada, and included in the Board's Departmental Performance Report, is consistent with these financial statements.

Management is also responsible for maintaining an effective system of internal control over financial reporting (ICFR) designed to provide reasonable assurance that financial information is reliable, that assets are safeguarded and that transactions are properly authorized and recorded in accordance with the Financial Administration Act and other applicable legislation, regulations, authorities and policies.

Management seeks to ensure the objectivity and integrity of data in its financial statements through careful selection, training and development of qualified staff; through organizational arrangements that provide appropriate divisions of responsibility; through communication programs aimed at ensuring that regulations, policies, standards, and managerial authorities are understood throughout the Board and through conducting an annual risk-based assessment of the effectiveness of the system of ICFR.

The system of ICFR is designed to mitigate risks to a reasonable level based on an ongoing process to identify key risks, to assess effectiveness of associated key controls, and to make any necessary adjustments.

The Patented Medicine Review Board is subject to periodic Core Control Audits performed by the Office of the Comptroller General and uses the results of such audits to comply with the Treasury Board Policy on Internal Control.

A Core Control audit was performed in 2011-12 by the Office of the Comptroller General of Canada (OCG). The Audit Report and related Management Action Plan are posted on the PMPRB's web site.

The financial statements of Patented Medicine Prices Review Board have not been audited.

Mary Catherine Lindberg
Chairperson
Ottawa, Canada
Date: August 30, 2012

Michelle Boudreau
Executive Director and Chief Financial Officer
Ottawa, Canada
Date: August 30, 2012

PATENTED MEDICINE PRICES REVIEW BOARD
Statement of Financial Position (Unaudited)
As at March 31


(in dollars)
2012 2011
Restated
(note 9)
Liabilities
Accounts payable and accrued liabilities (note 4) $ 3,744,189 $ 863,304
Vacation pay and compensatory leave 261,462 311,862
Employee future benefits (note 5) 915,844 1,184,685
Total gross liabilities 4,921,495 2,359,851
Liabilities held on behalf of Government
Accrued liabilities (note 4) (2,801,285) -
Total liabilities held on behalf of Government (2,801,285) -
Total net liabilities 2,120,210 2,359,851
Financial assets
Due from Consolidated Revenue Fund 460,841 742,931
Accounts receivable and advances (note 6) 154,258 141,406
Total net financial assets 615,099 884,337
Board net debt 1,505,111 1,475,514
Board net financial position $ (1,505,111) $ (1,475,514)

The accompanying notes form an integral part of these financial statements.

Mary Catherine Lindberg
Chairperson
Ottawa, Canada
Date: August 30, 2012

Michelle Boudreau
Executive Director and Chief Financial Officer
Ottawa, Canada
Date: August 30, 2012

PATENTED MEDICINE PRICES REVIEW BOARD
Statement of Operations and Board Net Financial Position (Unaudited)
For the Year Ended March 31

(in dollars) 2012
Planned Results
2012 2011
Restated
(note 9)
Expenses
Compliance and enforcement of non-excessive prices for patented drug products $ 8,170,345 $ 5,347,940 $ 4,732,092
Pharmaceutical trends analysis 1,640,354 1,457,407 1,225,587
Internal services 3,286,676 3,701,318 4,943,123
Total expenses 13,097,375 10,506,665 10,900,802

Revenues

Voluntary compliance undertakings - 8,394,187 23,272,642
Revenues earned on behalf of Government - (8,394,187) (23,272,642)
Total revenues - - -
Net cost of operations before government funding and transfers 13,097,375 10,506,665 10,900,802
Government funding and transfers
Net cash provided by Government of Canada 9,504,894 11,892,719
Change in due from Consolidated Revenue Fund (282,090) (2,448,980)
Services provided without charge by other government departments (note 7) 1,254,264 1,201,791
Net cost of operations after government funding and transfers 29,597 255,272
Board net financial position - Beginning of year (1,475,514) (1,220,242)
Board net financial position - End of year $ (1,505,111) $ (1,475,514)

Segmented information (note 8)

The accompanying notes form an integral part of these financial statements.

PATENTED MEDICINE PRICES REVIEW BOARD
Statement of Change in Board Net Debt (Unaudited)
For the Year Ended March 31

(in dollars) 2012 2011
Net cost of operations after government funding and transfers $ 29,597 $ 255,272
Net increase (decrease) in Board net debt 29,597 255,272
Board net debt - Beginning of year 1,475,514 1,220,242
Board net debt - End of year $ 1,505,111 $ 1,475,514

The accompanying notes form an integral part of these financial statements.

PATENTED MEDICINE PRICES REVIEW BOARD
Statement of Cash Flows (Unaudited)
For the Year Ended March 31

(in dollars) 2012 2011
Restated
(note 9)
Operating activities
Net cost of operations before government funding and transfers $ 10,506,665 $ 10,900,802
Non-cash items:
Services provided without charge by other government departments (note 7) (1,254,264) (1,201,791)
Variations in Statement of Financial Position:
Increase (decrease) in accounts receivable and advances 12,852 (68,701)
Decrease (increase) in accounts payable and accrued liabilities (79,600) 2,517,780
Decrease (increase) in vacation pay and compensatory leave 50,400 (33,568)
Decrease (increase) in employee future benefits 268,841 (221,803)
Cash used in operating activities 9,504,894 11,892,719
Net cash provided by Government of Canada $ 9,504,894 $ 11,892,719

The accompanying notes form an integral part of these financial statements.

PATENTED MEDICINE PRICES REVIEW BOARD
Notes to the Financial Statements (Unaudited)
For the Year Ended March 31, 2012

1. Authority and objectives

The Patented Medicine Prices Review Board (PMPRB) is an independent quasi-judicial body established by Parliament in 1987 under the Patent Act (Act).

Although the PMPRB is part of the Health Portfolio, it carries out its mandate at arms-length from the Minister of Health. It also operates independently of other bodies such as Health Canada, which approves drugs for safety and efficacy, and public drug plans, which approve the listing of drugs on their respective formularies for reimbursement purposes.

Strategic Outcome: Canadians and their health care system are protected from excessive prices for patented drug products sold in any market in Canada and key stakeholders are informed by pharmaceutical trends analysis.

Compliance and enforcement of non-excessive prices for patented drug products

The PMPRB is responsible for regulating the non-excessive average prices for patented drug products sold in Canada for human or veterinary use. Through this program activity, the PMPRB reviews the prices that patentees charge for patented drug products, based on the price review factors in the Patent Act, to ensure that these prices are not excessive. In the event that the Board finds, following a public hearing, that a price is excessive in any market, it may order the patentee to reduce the price and take measures to offset any excess revenues it may have received as a result of excessive prices.

Pharmaceutical trends analysis

The PMPRB conducts research and analysis on pharmaceutical trends and reports annually to Parliament through the Minister of Health on pharmaceutical trends and research and development spending by pharmaceutical patentees. Through the National Prescription Drug Utilization Information System (NPDUIS), the PMPRB also conducts research and provides critical analyses of price, utilization and cost trends for both patented and non-patented prescription drugs.

Internal services

Internal services are groups of related activities and resources that are administered to support the needs of programs and other corporate obligations of an organization. These groups are: Management and Oversight Services; Communications Services; Legal Services; Human Resources Management Services; Financial Management Services; Information Management Services; Information Technology Services; Real Property Services; Materiel Services; Acquisition Services; and Travel and Other Administrative Services. Internal Services include only those activities and resources that apply across an organization and not to those provided specifically to a program.

2. Summary of significant accounting policies

These financial statements have been prepared using the Government's accounting policies stated below, which are based on Canadian public sector accounting standards. The presentation and results using the stated accounting policies do not result in any significant differences from Canadian public sector accounting standards.

Significant accounting policies are as follows:

(a) Parliamentary authorities

The Patented Medicine Prices Review Board is financed by the Government of Canada through Parliamentary authorities. Financial reporting of authorities provided to the Board do not parallel financial reporting according to generally accepted accounting principles since authorities are primarily based on cash flow requirements. Consequently, items recognized in the Statement of Financial Position and the Statement of Operations and Board Net Financial Position are not necessarily the same as those provided through authorities from Parliament. Note 3 provides a reconciliation between the bases of reporting. The planned results amounts in the Statement of Operations and Board Net Financial Position are the amounts reported in the future-oriented financial statements included in the 2011-12 Report on Plans and Priorities.

(b) Net cash provided by Government

The Board operates within the Consolidated Revenue Fund (CRF), which is administered by the Receiver General for Canada. All cash received by the Board is deposited to the CRF and all cash disbursements made by the Board are paid from the CRF. The net cash provided by Government is the difference between all cash receipts and all cash disbursements including transactions between departments of the Government.

(c) Amounts due from the Consolidated Revenue Fund

Amounts due from the CRF are the result of timing differences at year-end between when a transaction affects authorities and when it is processed through the CRF. Amounts due from the CRF represent the net amount of cash that the Board is entitled to draw from the CRF without further authorities to discharge its liabilities.

(d) Revenues

  • Revenues from regulatory fees are recognized in the accounts based on the services provided in the year;
  • Other revenues are accounted for in the period in which the underlying transaction or event that gave rise to the revenue takes place;
  • Revenues that are non-respendable are not available to discharge the Board's liabilities. While the Deputy Head is expected to maintain accounting control, he or she has no authority regarding the disposition of non-respendable revenues. As a result, non-respendable revenues are considered to be earned on the behalf of the Government of Canada and are therefore presented in reduction of the entity's gross revenues.

(e) Expenses

Expenses are recorded on the accrual basis:

  • Vacation pay and compensatory leave are accrued as the benefits are earned by employees under their respective terms of employment;
  • Services provided without charge by other government departments for accommodation and the employer contribution to the health and dental insurance plans are recorded as operating expenses at their estimated cost.

(f) Employee future benefits

  1. Pension benefits: Eligible employees participate in the Public Service Pension Plan, a multiemployer pension plan administered by the Government. The Board's contributions to the Plan are charged to expenses in the year incurred and represent the total departmental obligation to the Plan. The Board's responsibility with regard to the Plan is limited to its contributions. Actuarial surpluses or deficiencies are recognized in the financial statements of the Government of Canada, as the Plan's sponsor.
  2. Severance benefits: Employees entitled to severance benefits under labour contracts or conditions of employment earn these benefits as services necessary to earn them are rendered. The obligation relating to the benefits earned by employees is calculated using information derived from the results of the actuarially determined liability for employee severance benefits for the Government as a whole.

(g) Accounts receivable

Accounts receivable are stated at the lower of cost and net recoverable value. They are mainly comprised of amounts to be recovered from other government departments and the recovery is considered certain. As a result, no provision has been recorded as an offset against these amounts.

(h) Contingent liabilities

Contingent liabilities are potential liabilities which may become actual liabilities when one or more future events occur or fail to occur. To the extent that the future event is likely to occur or fail to occur, and a reasonable estimate of the loss can be made, an estimated liability is accrued and an expense recorded. If the likelihood is not determinable or an amount cannot be reasonably estimated, the contingency is disclosed in the notes to the financial statements.

(i) Measurement uncertainty

The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in the financial statements. At the time of preparation of these statements, management believes the estimates and assumptions to be reasonable. The most significant item where estimates are used is the liability for employee severance benefits. Actual results could significantly differ from those estimated. Management´s estimates are reviewed periodically and, as adjustments become necessary, they are recorded in the financial statements in the year that they become known.

3. Parliamentary authorities

The Patented Medicine Prices Review Board receives most of its funding through annual parliamentary authorities. Items recognized in the Statement of Financial Position and the Statement of Operations and Board Net Financial Position in one year may be funded through parliamentary authorities in prior, current or future years. Accordingly, the Board has different net results of operations for the year on a government funding basis than on an accrual accounting basis. The differences are reconciled in the following tables:


(a) Reconciliation of net cost of operations to current year authorities used:
(in dollars) 2012 2011
Restated
(note 9)
Net cost of operations before government funding and transfers $ 10,506,665 $ 10,900,802
Adjustments for items affecting net cost of operations but not affecting authorities:
Services provided without charge by other government departments (1,254,264) (1,201,791)
Decrease (increase) in vacation pay and compensatory leave 50,400 (33,568)
Decrease (increase) in employee future benefits 268,841 (221,803)
Refund/adjustment of previous year´s expenditures 21,855 27,067
Workforce adjustment measures (352,000) -
Total items affecting net cost of operations but not affecting authorities 9,241,497 9,470,707
Adjustments for items not affecting net cost of operations but affecting authorities:
Refund of previous year revenue 2,512,878 -
Current year authorities used $ 11,754,375 $ 9,470,707
(b) Authorities provided and used:
(in dollars) 2012 2011
Authorities provided:
Vote 35 - Program expenditures $ 11,735,590 $ 11,605,136
Statutory amounts 3,513,329 942,747
Less:
Lapsed authorities (3,494,544) (3,077,176)
Current year authorities used $ 11,754,375 $ 9,470,707

4. Accounts payable and accrued liabilities

The following table presents details of Patented Medicine Prices Review Board's accounts payable and accrued liabilities:

(in dollars) 2012 2011
Accounts payable - external parties $ 361,346 $ 627,588
Accounts payable - other government departments and agencies 7,071 31,648
Total accounts payable 368,417 659,236
Accrued liabilities 3,375,772 204,068
Gross accounts payable and accrued liabilities 3,744,189 863,304
Accrued liabilities held on behalf of government (2,801,285) -
Total accounts payable and accrued liabilities $ 942,904 $ 863,304

In Canada's Economic Action Plan 2012, the Government announced savings measures to be implemented by departments over the next three fiscal years starting in 2012-13. As a result, the Board has recorded at March 31, 2012 an obligation for termination benefits for an amount of $352,000 as part of accrued liabilities to reflect the estimated workforce adjustment costs.

The Board has recorded an accrued liability of $2.8 million in 2011-12 (nil for 2010-11) for an allowance for claims and litigation.

5. Employee future benefits

(a) Pension benefits

The Board's employees participate in the Public Service Pension Plan, which is sponsored and administered by the Government. Pension benefits accrue up to a maximum period of 35 years at a rate of 2% per year of pensionable service, times the average of the best five consecutive years of earnings. The benefits are integrated with Canada/Québec Pension Plans benefits and they are indexed to inflation.

Both the employees and the Board contribute to the cost of the Plan. The current and previous year expenses, which represent approximately 1.8 times (1.9 times in 2010-11) the contributions by employees, amount to:

(in dollars) 2012 2011
Expense for the year $ 685,591 $ 661,739

The Board's responsibility with regard to the Plan is limited to its contributions. Actuarial surpluses or deficiencies are recognized in the financial statements of the Government of Canada, as the Plan's sponsor.

(b) Severance benefits

The Board provides severance benefits to its employees based on eligibility, years of service and salary at termination of employment. These severance benefits are not pre-funded. Benefits will be paid from future authorities. Information about the severance benefits, measured as at March 31, is as follows:

As part of collective agreement negotiations with certain employee groups, and changes to conditions of employment for executives and certain non-represented employees, the accumulation of severance benefits under the employee severance pay program ceased for these employees commencing in 2012. Employees subject to these changes have been given the option to be immediately paid the full or partial value of benefits earned to date or collect the full or remaining value of benefits on termination from the public service. These changes have been reflected in the calculation of the outstanding severance benefit obligation.

(in dollars) 2012 2011
Accrued benefit obligation - Beginning of year $ 1,184,685 $ 962,882
Expense for the year 122,288 383,537
Benefits paid during the year (391,129) (161,734)
Accrued benefit obligation - End of year $ 915,844 $ 1,184,685

6. Accounts receivable and advances

The following table presents details of Patented Medicine Prices Review Board's accounts receivable and advances balances:

(in dollars) 2012 2011
Accounts receivable - other government departments and agencies $ 153,758 $ 140,906
Employee advances 500 500
Net accounts receivable and advances $ 154,258 $ 141,406

7. Related party transactions

The Board is related as a result of common ownership to all Government of Canada departments, agencies, and Crown corporations. The Board enters into transactions with these entities in the normal course of business and on normal trade terms. Also, during the year, the Board received services which were obtained without charge from other government departments as disclosed below.

(a) Common services provided without charge by other government departments:

During the year, the Board received services without charge from certain common service organizations, related to accommodation, legal services and the employer's contribution to the health and dental insurance plans. These services provided without charge have been recorded in the Board's Statement of Operations and Board Net Financial Position as follows:

(in dollars) 2012 2011
Accommodation $ 723,952 $ 716,212
Employer's contribution to the health and dental insurance plans 510,632 485,543
Legal Services 19,680 36
Total $ 1,254,264 $ 1,201,791

The Government has centralized some of its administrative activities for efficiency, cost-effectiveness purposes and economic delivery of programs to the public. As a result, the Government uses central agencies and common service organizations so that one department performs services for all other departments and agencies without charge. The costs of these services, such as the payroll and cheque issuance services provided by Public Works and Government Services Canada, are not included in the Board's Statement of Operations and Board Net Financial Position.

(b) Other transactions with related parties:

(in dollars) 2012 2011
Accounts receivable - other government departments and agencies $ 153,758 $ 140,906
Accounts payable - other government departments and agencies 7,071 31,648
Expenses - other government departments and agencies 142,319 194,972

Expenses and revenues disclosed in (b) exclude common services provided without charge, which are already disclosed in (a).

8. Segmented information

(in dollars) Compliance and enforcement of non-excessive prices for patented drug products Pharmaceutical trends analysis Internal services 2012
Total
2011 Total Restated
(note 9)
Expenses
Salaries and employee benefits $ 3,960,454 $ 1,171,425 $ 2,422,882 $ 7,554,761 $ 7,395,566
Professional and special services 713,386 107,274 700,744 1,521,404 1,941,097
Accommodation 402,195 80,439 241,317 723,951 716,212
Utilities, materials and supplies 183,756 66,750 60,424 310,930 465,191
Purchased repair and maintenance - - 139,135 139,135 137,812
Travel and relocation 23,835 7,135 63,132 94,102 93,985
Communications 13,379 1,072 62,319 76,770 91,587
Other 46,871 - 417 47,288 (459)
Information services 564 22,267 3,444 26,275 48,120
Rentals 3,500 1,045 7,504 12,049 11,691
Total expenses 5,347,940 1,457,407 3,701,318 10,506,665 10,900,802
Revenues
Voluntary compliance undertakings (5,314,163) - 13,708,350 8,394,187 23,272,642
Revenues earned on behalf of Government 5,314,163 - (13,708,350) (8,394,187) (23,272,642)
Total revenues - - - - -
Net cost of operations $ 5,347,940 $ 1,457,407 $ 3,701,318 $ 10,506,665 $ 10,900,802

9. Accounting changes

During 2011, amendments were made to Treasury Board Accounting Standard 1.2––Departmental and Agency Financial Statements to improve financial reporting by government departments and agencies. The amendments are effective for financial reporting of fiscal years ending March 31, 2012, and later. The significant changes to the Board´s financial statements are described below. These changes have been applied retroactively, and comparative information for 2010-11 has been restated.

Net debt (calculated as liabilities less financial assets) is now presented in the Statement of Financial Position. Accompanying this change, the Board now presents a Statement of Change in Net Debt and no longer presents a Statement of Equity.

Revenue is now presented net of non-respendable amounts in the Statement of Operations and Board Net Financial Position. The effect of this change was to increase the net cost of operations before government funding and transfers by $8,394,187 for 2011-12 ($23,272,642 for 2010-11).

Government funding and transfers, as well as the credit related to services provided without charge by other government departments, are now recognized in the Statement of Operations and Board Net Financial Position below “Net cost of operations before government funding and transfers.” In previous years, the Board recognized these transactions directly in the Statement of Equity of Canada. The effect of this change was to decrease the net cost of operations after government funding and transfers by $7,675,783 for 2011-12 ($10,645,530 for 2010-11).

(in dollars) 2011
As previously stated
Effect of change 2011
Restated
Statement of Operations and Board Net Financial Position
Revenues $ 23,272,642 $ (23,272,642) $ -
Government funding and transfers
Net cash provided by Government - 11,892,719 11,892,719
Change in due from Consolidated Revenue Fund - (2,448,980) (2,448,980)
Services provided without charge by other government departments $ - $1,201,791 $1,201,791

10. Comparative information

This fiscal year it was noted that the reporting in the Statement of Operations for 2010-11 was presented in such a manner which warranted a restatement. The modification affects the allocation between program activities, and has a nil effect on total expenses. Consequently, the comparative financial statements for the year ended March 31, 2012 have been reclassified. The effect of these adjustments is presented in the table below.

(in dollars) As previously stated Effect of change 2011
Reclassified
Statement of Operations and Board Net Financial Position/Segmented information
Expenses
Compliance and enforcement of non-excessive prices for patented drug products $1,517,726 $3,214,366 $4,732,092
Pharmaceutical trends analysis 4,439,953 (3,214,366) 1,225,587
Date modified: